Advancing Diagnostic Precision in Breast Imaging

GENERAL COURSE DESCRIPTION

This accredited CME activity provides a structured, case-based learning experience focused on improving early breast cancer detection through imaging–pathology correlation.

 

The program consists of four 30-minute enduring modules followed by a 30-minute live virtual Q&A session. Participants will review diagnostic challenges in mammography and ultrasound with emphasis on interpretive accuracy, evaluation of calcifications without mass, and differentiation of benign and malignant morphologic patterns.

 

The enduring modules are delivered asynchronously through the iiCME Learning Platform. The live Q&A session provides an opportunity for interactive discussion and clarification of key concepts.

Instructional Objectives — upon completion of this activity, participants should be able to:

1. 1. Describe the site of origin of breast cancers and its implications for early detection.
   2. Apply principles of imaging–pathology correlation to mammography and ultrasound cases.
   3. Evaluate calcifications without associated mass using structured interpretive frameworks.
   4. Differentiate benign and malignant morphologic patterns based on radiologic criteria.

 

Target Audience

This course is intended for, Radiologists, Breast imaging specialists, Diagnostic imaging physicians, Radiology fellows and trainees

 

ACCREDITATION & CREDIT DESIGNATION

Accreditation

The International Institute for Continuing Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The International Institute for Continuing Medical Education, Inc. designates this activity for a maximum of 2.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Educational Format & Time Allocation

Total Educational Time: 2.5 hours

• 2.0 hours — Enduring modules (four 30-minute sessions)
• 0.5 hours — Live virtual Q&A

 

EVENT CALENDAR

This activity will be available on demand beginning March 6, 2026, with enduring access through March 6, 2027.

A live virtual Q&A session with Dr. László Tabár will take place on March 26, 2026 at 10:00 AM Central Time.

All educational content and the live session will be delivered online through the iiCME Learning Platform (AltusCampus).

Registration information and other details will be sent post registration.

REGISTRATION

Registration for this activity is open.

Enrollment is complimentary and available at no cost. Learners must register directly through the iiCME registration form below.

The enduring modules will be delivered through the AltusCampus online learning platform. The live virtual Q&A session will be hosted via Microsoft Teams Town Hall.

An enrollment code will be provided in the registration confirmation email to enable access to the course content. All registration communications, processing, and learner data collection occur exclusively through iiCME and the AltusCampus learning platform.

 

SPEAKERS

László Tabár, MD, PhD, FACR (Hon.)

Professor Emeritus of Radiology

Uppsala University Faculty of Medicine

Uppsala, Sweden

 

AGENDA STRUCTURE

Enduring Modules (Available March 6, 2026)

Module 1 — Imaging–Pathology Correlation in Early Breast Cancer

Module 2 — Evaluation of Calcifications Without Mass

Module 3 — Morphologic Differentiation: Benign vs. Malignant Patterns

Module 4 — Diagnostic Frameworks for Clinical Practice

Live Virtual Q&A

Interactive Q&A discussion session with Dr. Tabár

Thursday March 26 at 10: AM CST

 

COMMERCIAL SUPPORT

This activity is supported by an unrestricted educational grant from Ikonopedia.

The commercial supporter had no role in the planning, content development, faculty selection, or execution of this activity.

DISCLOSURE

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and reviewers disclose relevant financial relationships with ineligible companies.

 

All relevant financial relationships have been identified and mitigated prior to the start of this activity.